Login to Your Account



Archimedes Breakthrough Pain Drug Gets Pain-Free REMS

By Mari Serebrov and Nuala Moran


Wednesday, July 6, 2011
Archimedes Pharma Ltd.'s Lazanda isn't the first fentanyl product to get the FDA's nod for breakthrough cancer pain, but its pain-free risk evaluation and mitigation strategy (REMS) and intranasal delivery could give it an edge in the U.S. market once it launches in the fall.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription